We deliver…

We deliver…



NTrans Technologies BV


Utrecht, The Netherlands


NTrans Technologies BV was founded in 2015 based on a proprietary platform technology for the intracellular delivery of bioactive molecules developed at the Hubrecht Institute of the Royal Netherlands Academy of Sciences.


We are further developing this technology for both research and clinical purposes as a method for the delivery of biologicals that is safe, non-toxic, highly efficient, and easy to use.


Our goal is to be a leader in technologies for the transduction of proteins and other bioactive molecules into primary cells.


We offer licensing of the unique transduction platform with thorough technical support to optimize your transduction.


Prof. John van der Oost about CRISPR-Cas technology


John van der Oost (Scientific Advisor and Co-founder) of NTrans Technologies about CRISPR-Cas technology in “Analyse Nederland”: https://analysenederland.nl/article/john-van-der-oost-darwin-zou-crispr-cas-technologie-juist-fantastisch-vinden.html

NTrans joins H2020 project: iPSpine


On February 12th and 13th, the kick-off of an international, 15-million-euro, 20-partner project titled iPSpine (Induced pluripotent stem cell-based therapy for spinal regeneration) was held in Utrecht, The Netherlands. This 5-year project falls under the European Union’s Horizon 2020 programme to fund research that improves knowledge, testing, and exploitation platforms that address the future of

Read more